Attendee search 

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.

We have successfully completed our first Phase 3 clinical trial for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.

 Trius is headquartered in San Diego, California. 

Principia Biopharma is building an integrated pharmaceutical company focused on the discovery and development of reversible covalent drugs for the treatment of autoimmune diseases and cancer.  Principia’s reversible covalent technology, which has been validated in vivo against multiple targets to date, produces molecules with superior attributes and our approach has significant advantages over standard drug development methods. 

o   It produces highly potent (low nanomolar to picomolar) compounds with increased selectivity and prolonged durability despite limited exposure.

o   Accelerates the drug development process by avoiding the need for HTS and the  provides the opportunity to evolve tool compounds into clinical candidates

o   Has a broad range of applicability across multiple target classes

Given the wealth of opportunities addressable with Principia’s technology, the company is interested in working with partners to fully exploit the technology outside of cancer and autoimmune therapeutic areas.

Laureate Biopharma is a leader in biopharmaceutical contract development and manufacturing with more than 30 years of experience. Our scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, our portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and full regulatory support. Laureate has served a global client base from its Princeton, New Jersey facility since 1981. Laureate is a portfolio company of Saints Capital, LLC.

Xcovery Vision is developing small molecule kinase inhibitors for opthamology indications. We have 4-5 canidates licensed exclusively to Xcovery Vision from Xcovery for the purpose of developing drugs for several eye diseases.

We are a spin out of Xcovery the parent oncology company founded by Sheridan Snyder founder of Genzyme and Dr. Chris Liang developer of Sutent, Pfizer's leading kidney cancer drug.

We are developing a oral drug for AMD which will be going into a Phase 1B trial this October. 

Please visit our website for more information www.xcoveryvision.com

Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. The firm’s clients include all of the world’s top-20 pharmaceuti­cal companies, hundreds of emerging and midsize biopharmaceutical companies, as well as a number of medical device and diagnostics companies. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Clinical Development, Commercial Effectiveness, Corporate Development, Medical Affairs, and Pricing and Market Access. From its locations in Cambridge, MA; Conshohocken, PA; Deerfield, IL; London, UK; Newtown, PA; New York, NY; Parsippany, NJ; Raleigh, NC; Somerset, NJ; South San Francisco, CA; Thousand Oaks, CA; and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan.

Foley Hoag is a preeminent Life Sciences law firm that represents public and private clients in a wide range of transactions worldwide.  The chair of our Licensing and Strategic Alliances practice group together with one of our leading Intellectual Property partners will be available to meet with interested companies.

Novartis Oncology profile

 A business unit within the Novartis Group, Novartis Oncology delivers a broad range of innovative therapies and practical solutions that help change the way patients live with cancer and blood disorders. Glivec® (imatinib) is an oral treatment for multiple rare diseases including forms of Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia (CML) and Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Tasigna® (nilotinib) is approved for Ph+ CML adult patients resistant to or intolerant to at least one prior therapy. Afinitor® (everolimus) is indicated for patients with advanced renal cell carcinoma whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy. Zometa® (zoledronic acid) is indicated for the prevention of skeletal-related events in patients with advanced malignancies involving bone. Zometa also treats hypercalcemia of malignancy. Femara® (letrozole) is approved for adjuvant treatment of hormone receptor positive early breast cancer as well as for extended adjuvant treatment of hormone receptor positive early breast cancer after five years of initial tamoxifen therapy. It is also approved for several uses in certain postmenopausal women with advanced breast cancer. Sandostatin® LAR® (octreotide) helps control symptoms, such as severe diarrhea and flushing, associated with functional gastroenteropancreatic neuroendocrine tumors. It is also approved for the treatment of acromegaly. Exjade® (deferasirox) is approved to treat iron overload in a broad range of patients receiving ongoing blood transfusions. Novartis Oncology has a robust pipeline that utilizes recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.

Partnering strategy

Novartis Oncology is seeking to license or acquire targeted therapeutic approaches to cancer treatment, with a particular interest in projects that have demonstrated Proof-of-Concept in human trials.

Jaleva Pharmaceuticals is a company focused on the improved delivery of active ingredients to the skin or mucosa.  We achieve this with our Patented Resin technology, and do so topically, and transmucosally.  The core of our Delivery is fast acting, and long lasting delivery of API's.

We currently have three products ready for license.  

1. A Surgical Prep product to compete with Chloraprep.

2. A Topical Pain Relief Spray, for two times a day use.

3. An NRT Trans-buccal product, quick acting, mimicking the craving reduction of a cigarette.

We have an array of other products in our development pipeline.